Faeth Therapeutics, Inc.
FTH · Biotech · Nasdaq · As of 10 Sep 2026
- FundamentalsNot enough data yet
- ValueNot enough data yet
- News flowBalanced
- MomentumStrong
- SafetyBalanced
Overall confidence 25/100 — few inputs available yet
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.
Discovery Gap: Low (0/100) · Gap confidence 0/100The market has largely caught up to the documented story.
This month at a glance
AIR Score™ change: -1Slipped -1 on softer inputs.
Cycle window9 Sep 2026 → 10 Sep 2026
Momentum-1Weighed on the latest score.
Evidence timeline
No documented events on file yet.
Ask AIR
What would change our view
A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.